O'Brien Oisín, Arumuham Atheeshaan, Mizuno Yuya, Baxter Luke, Lobo Maria, Parmar Sita, Jolles Stephen, Howes Oliver D
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; South London and Maudsley NHS Foundation Trust, London, UK; and Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, UK.
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; South London and Maudsley NHS Foundation Trust, London, UK; and Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
BJPsych Open. 2024 Feb 16;10(2):e49. doi: 10.1192/bjo.2024.10.
This prospective study examines the immune response to SARS-CoV-2 vaccination in patients with psychotic disorders compared with healthy volunteers. Participants were recruited naturalistically as part of the UK's COVID-19 vaccination programme. Prior to receiving their first COVID-19 vaccine, blood samples were provided by participants to examine anti-SARS-CoV-2 immunoglobulins (IgG) at baseline, followed by a repeat assay 1 month after receiving their first vaccine to assess vaccine response. The increase of IgG levels from baseline to 1 month post-vaccination was significantly lower in patients compared with controls, supporting evidence of impaired vaccine response in people with psychotic disorders. When excluding patients treated with clozapine from the analysis, this difference was no longer significant, suggesting that effects may be particularly marked in people taking clozapine.
这项前瞻性研究将精神病患者与健康志愿者进行对比，考察了他们对SARS-CoV-2疫苗接种的免疫反应。参与者是作为英国COVID-19疫苗接种计划的一部分自然招募的。在接种第一剂COVID-19疫苗之前，参与者提供血样以检测基线时的抗SARS-CoV-2免疫球蛋白（IgG），然后在接种第一剂疫苗1个月后进行重复检测以评估疫苗反应。与对照组相比，患者从基线到接种疫苗后1个月IgG水平的升高显著更低，这支持了精神病患者疫苗反应受损的证据。在分析中排除接受氯氮平治疗的患者后，这种差异不再显著，这表明在服用氯氮平的人群中影响可能尤为明显。
